Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (noted as TALPHERA, INC. in metadata) on November 9, 2018. The report details a significant capital raising event involving the public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 12,698,412 shares of common stock.
- Public Offering Price: $3.15 per share.
- Price to Company: $2.961 per share.
- Underwriters' Option: An option to purchase up to 1,904,761 additional shares was granted and exercised in full on November 12, 2018.
- Total Shares Sold: 14,603,173 shares (Initial offering + Full option exercise).
- Underwriters: Credit Suisse Securities (USA) LLC and Jefferies LLC.
- Closing Date: Expected November 14, 2018.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures. It focuses solely on the equity transaction.
Material Changes
The primary material change is the increase in the company's share count and the influx of capital resulting from the underwritten public offering. The full exercise of the underwriters' option increased the total capital raised beyond the initial offering size.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operations, or a discussion of risks beyond standard underwriting agreement terms. The transaction is subject to customary closing conditions and representations, warranties, and indemnification obligations typical of such agreements.
Investor Verification Checklist
- Verify the final closing date of the offering (expected November 14, 2018) and the actual net proceeds received.
- Confirm the updated total share count and diluted ownership structure following the issuance of 14,603,173 shares.
- Review the Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or other covenants imposed on the company.
- Check subsequent filings for the use of proceeds from this capital raise.